Portfolio Choice  123    15   

Published: Sep 30, 2022
Updated: Sep 30, 2022

ASTRAZENECA PHARMA INDIA
BSE ticker code 506820
NSE ticker code ASTRAZEN
Major activity Pharmaceuticals
Managing Director Narayan K. Seshadri
Equity capital Rs. 5.00 crore; FV Re. 02
52 week high/low Rs. 3375 / Rs. 2437
CMP Rs. 3302.00
Market Capitalisation Rs. 8255.00 crore
Recommendation Accumulate at declines
Focus on crucial health molecules

Bengaluru-headquartered AstraZeneca Pharma is a subsidiary of AstraZeneca Ple UK, a $37,417 billion-insales MNC pharmaceutical giant having a portfolio of products for major diseases in areas including oncology, cardiovascular, gastro-intestinal, infection, neuroscience, respiratory and inflammation. It has been involved in developing the Oxford-AstraZeneca Covid-19 vaccine. A BSE-listed company which has a workforce of 1,400 across the country, it is committed to providing life-changing medicines to patients through innovative science and global excellence in development and commercialization. The company has an innovative portfolio in crucial areas of healthcare, including cardiovascular, renal and metabolic diseases, oncology and respiratory. The company’s Bengaluru manufacturing facility has been rated the finest in Southeast Asia with a state-of-theart production facility that meets stringent international standards, including WHO-Good Manufacturing Practices (GMP) norms. Some of the company’s key brands include Forxiga, Brilinta, Imfinzi, Lynparza, Xigaduo Qutern and Zoladex.

The company has been going from strength to strength on the sales front, with the turnover steadily expanding from Rs 594 crore in fiscal 2011 to Rs 806 crore in fiscal 2022. However, its performance on the profitability front is disappointing, with its operating profit which was Rs 104 crore in fiscal 2011 turning negative in fiscal 2013 with a loss of Rs 68 crore and remaining in the red for the next year. However, subsequently, the company has started earning a profit which gradually edged up to Rs 135 crore in fiscal 2021 before declining to Rs 86 crore in fiscal 2022. Its prospects going ahead are highly promising.

Consider:

  • Going ahead, the company will continue to prioritise investments in its focus areas in line with its global growth platforms. Accordingly, new products remain a key priority and it is committed to maintaining alignment with the global pipeline, subject to conduct of clinical trials, regulatory approvals and reasonable commercial viability. A strong product pipeline in respiratory is expected to drive significant growth in the coming years.
  • The company has joined hands with the NASSCOM Centre of Excellence and the partnership has led to the discovery of three start- ups.
  • The growth platform of the company is performing well, with innovative molecules like Brilinta, Forxiga, Kigduo, Symbicort, Symbicartin and Komblgyze. The newer launches of innovative molecules like Tagrisso, Lynporza and Imitinzi have helped it make an impact on the lives of patients. Brilinta is approved for treatment in acute coronary syndrome and high-risk post-MI patients, and continues to register rapid growth even after loss of exclusivity.
  • The company has been entering into strategic tie-ups to enrich its business portfolio. It is on an expansion spree as it is eyeing several deals which would be beneficial to it. Recently, it collaborated with Bangalore-based Cellworks to jointly work on designing combination therapies to treat drug- sensitive and resistant tuberculosis. Farther, the company is engaged in signing deals with companies like GlaxoSmithKline and Amylin Pharmaceuticals in order to add external pieces to their pharmaceutical portions. The company’s partnership with Sun Pharma Laboratories has helped boost the reach of a crucial drug to more patients. This franchise has become the market leader by value share in oral anti-platenets, as per Iqvia Health.
  • The parent company has undertaken a very ambitious plan to more than double its new cancer drugs by 2030. In order to seek the top slot in the world’s most lucrative category of medicines, AstraZeneca has added seven new cancer medicines since 2014 after the company’s CEO Pascal Sariot warded off a hostile takeover from Pfizer Inc. Now, with blockbuster treatments for malignancies in the lungs, ovaries and blood, AstraZeneca aspires to be the fastest growing maker of cancer drugs. The company has thus the opportunity to be the No 1 oncology player. The Indian outfit will benefit considerably when the parent company achieves its aim by 2030, as the menace of cancer is fast growing in India.

The increasing incidence and diagnosis of NCDs, strategic partnerships from foreign players with local players, initiatives to improve access to healthcare and medicines, a positive outlook of the regulatory environment, associated new drug launches, implementation of robust digital healthcare initiatives, and expansion of the healthcare infrastructure are some of the factors that will drive growth in the sector in general and in AstraZeneca in particular. The key contributors to the growth of the company will be rising income levels, greater health awareness, increased presence of lifestyle diseases and improved access to insurance.

PERFORMANCE INDICATORS (Rs. in crore)

Year Net Sales Net Profit EPS (Rs.) Div (%) BV (%) RONW (%)
2019-20 831.80 72.00 28.80 50.0 145.80 21.70
2020-21 813.60 91.70 36.70 100.0 182.50 22.40
2021-22 805.60 59.51 23.80 500.0 204.60 12.30
COCHIN SHIPYARD
BSE ticker code 521064
NSE ticker code TRIDENT
Major activity Other Textile Products
Chairman Rajinder Gupta
Equity capital Rs. 509.60 crore; FV Re. 01
52 week high/low Rs. 71 / Rs. 13
CMP Rs. 51.75
Market Capitalisation Rs. 26371.57 crore
Recommendation Buy at declines
Expanding shipbuilding footprint

The government of India-owned miniratna PSU, Cochin Shipyard, is the largest shipbuilding and ship repair facility in the country. It is the sole shipyard in the country which is managed by the Ministry of Ports. The company has built platform supply vessels and double-hulled oil tankers. It is also a well-known player on the global ship-building front and has by now exported over 45 ships to various commercial clients overseas. The company’s performance on the financial front is also heart-warming. What is more, prospects for this mid-cap company are quite promising going ahead.

Consider:

  • The company has built and repaired some of the largest ships in India and also the prestigious indigenous aircraft carrier for the Indian Navy. Over the years, it has successfully responded to fluctuations in the ship-building requirements of the market and has evolved from building bulk carriers to smaller and more technically sophisticated vessels such as passenger vessels and offshore support vessels. The company has worked with several leading technology firms in the industry, including Royce Marine (Norway), GTT (France) and Yard Group (Norway). This has added to its credibility in the international markets. Its key ship-building clients in the domestic space include the Indian Navy, the Indian Coast Guard, DRDO, A&N Administration and the JSW group. The company has a robust order book with pending orders worth over Rs 10,000 crore and enquiries in addition to benefits it will get from ‘Make in India’, ‘Atmanirbhar Bharat’ and indigenous defence orders.
  • The Indian ship-building industry continues to be driven by defence requirements. The Indian Navy is planning to increase its fleet from the present 137 to 200 by 2027. This is expected to provide a spurt to the indigenous ship-building segment. Besides, the Indian Navy’s indigenisation plan is expected to give a fillip to the growth of ancillaries and generally improve the ship-building environment in the country
  • As per the AT Kearney report on the ship repair industry, though India’s share in global ship repair is less than 1%, the country’s location is favourable with 7-9% of global trade passing within 300 nautical miles of the coastline. According to the report, India has a market potential of Rs 2,600 crore from repairs to the domestic fleet, of which only a 15% share is currently captured. The report has further highlighted that India can grow its ship repair industry to Rs 9,000 crore in the next 10 years through infrastructure and process improvement. The report has highlighted low levels of process efficiency, lack of infrastructure to service vessels above 10,000 DWT and a weak ancillary landscape as road blocks for developing the industry. A key recommendation of the report was to lease out the repair facilities at major ports to specialists to augment revenue opportunities.
  • In line with the above recommendations, one of the major initiatives under the Government of India’s ‘Sagarmala’ project was to lease out the ship repair facilities available at the major ports to specialists to generate more revenue and create a positive ship repair industry climate. Based on this, CSL was offered the first opportunity for ship repair operations and management of the Indira Dock on January 18, 2019. CSL has also signed an MoU with Kolkata Port Trust to take over their Netaji Subhas Dock on lease.
  • According to research analysts of ICICI Securities, the defence PSU has remained resilient and is seen outperforming the broader market. It is performing very well with sales turnover during the last 12 years more than doubling from Rs 1,462 crore in fiscal 2011 to Rs 3,190 crore in fiscal 2022, operating profit also more than doubling from Rs 308 crore to Rs 637 crore during the same 12-year period, and the profit at net level shooting up more than two and a half times – from Rs 228 crore to Rs 587 crore. The compounded sales growth during the last 10 years works out to 9 per cent and the compounded profit growth around 14 per cent. The new fiscal year ending March 2023 has started on a highly cheerful note, with revenues in Q1 FY2023 registering a growth of 33.8 per cent yoy to Rs 440.9 crore, driven by a 31 per cent yoy growth in the shipbuilding segment and a 47 per cent yoy growth in the ship repair segment. EBITDA shot up by 50.6 per cent yoy to Rs 31.5 crore as the EBITDA margin improved to 7.1 per cent from 6.4 per cent in Q1 a year ago. Profit at the net level inched up by 47.2 per cent yoy to Rs 42.2 crore.
  • The company has been paying dividends regularly and the rate for the last year was Rs 16.75 per share. Interestingly, the company has been maintaining a healthy dividend payout of 35.1 per cent. The company’s stock is trading at 1.14 times its book value, which is quite attractive.

CONSOLIDATED PERFORMANCE INDICATORS (Rs. in crore)

Year Net Sales Net Profit EPS (Rs.) Div (%) BV (%) RONW (%)
2019-20 3422.50 632.00 48.00 166.0 283.00 14.40
2020-21 2818.90 599.20 45.50 155.0 306.60 15.50
2021-22 3190.95 565.99 43.00 168.0 334.00 13.43
TIME TECHNOPLAST
BSE ticker code 532856
NSE ticker code TIMETECHNO
Major activity Plastic Products Industrial
Managing Director Sanjay Kulkarni
Equity capital Rs. 22.61 ; FV Rs. 02
52 week high/low Rs. 126 / Rs. 63
CMP Rs. 119.95
Market Capitalisation Rs. 2712.63 crore
Recommendation Buy at declines
Polymer solutions for varied clients

Time Technoplast is an Indian multinational conglomerate engaged in the manufacture of technology-driven innovative polymer products, with operations in India, Bahrain, Egypt, Indonesia, Malaysia, UAE, Taiwan, Thailand, Vietnam, Saudi Arabia and the US, and more than 34 production facilities across the globe. These products cater to growing industry segments like industrial packaging solutions, life style products, automotive components, healthcare products, infrastructure/ construction-related products and material handling solutions.

Promoted by qualified professionals with decades of experience – who believe in working hard for the company, its customers, its suppliers, its employees and its shareholders — the company started as a small-scale unit with a production facility in Tarapur (Maharashtra) in 1993, and the very next year entered into a technological collaboration with the Mauser group. Then it started expanding its domestic footprint by setting up a plant at Daman (in the Union Territory of Diu and Daman) Hosur (Tamil Nadu) and Baddy (Himachal Pradesh). Having established itself in all parts of the country, Time Technoplast embarked on a strategic expansion overseas in the UAE, Bahrain and Thailand in order to serve its customers in the western, southern and south eastern regions of Asia. Having covered the Asian region, the company made inroads in Europe, the US and the Middle East. It also entered into a joint venture with the Mauser group to acquire to related businesses in other Asian countries. By now, it services over 500 institutional clients and its distribution/ dealer network is spread over 345 cities and towns.

The company has been going from strength to strength on the financial front, with its consolidated sales turnover during the last 12 years expanding from Rs 1,259 crore in fiscal 2011 to Rs 3,650 crore in fiscal 2022, with operating profit inching up from Rs 236 crore to Rs 506 crore during this period. What is more, prospects ahead are all the more encouraging.

Consider:

  • Time Technoplast does not have many competitors globally. Since its inception in 1992, it has set itself apart from the competition by focusing on R&D, futuristic product design and superior customer service by setting up 28 manufacturing units and 8 regional and marketing offices to meet the demand of Indian and global customers. The company focuses on longterm relationships with customers and has addressed the varied and expanding requirements of customers over a long period. By introducing new products, it has obtained additional business from existing customers and expanded into new markets.
  • The company has decided to restructure its overseas business in order to capture growth in Asia, the Middle East and the US through joint ventures/special purpose vehicles by onboarding strategic/investor partners by way of sales/transfer/disposal of part of assets/investments of subsidiaries/ material subsidiaries/step-down subsidiaries. This will enable the company to utilize the process of restructuring for repayment of debt, capex for composite cylinders (LPG, CNG/hydrogen) and its core business in India to meet the huge and expanding market demand. This will ultimately benefit its shareholders substantially.
  • The company has surplus land in Mumbai which it wants to dispose of. This, along with its overseas proceeds, will go a long way in wiping out its borrowings which amount to Rs 906 crore as on March 31, 2022.
  • Time Technoplast is a regular dividend payer, the rate for last year being 150 per cent. The decline in its debt will enable the management to step up dividends going ahead. The company’s financial position is very strong, with reserves at the end of March 2022 standing at Rs 2,050 crore – almost 90 times its equity capital of Rs 23 crore. The company has not made any bonus issue so far, and one is due now. Discerning investors will do well to include this scrip in their portfolio. Shares are available around Rs 117.

The future outlook for the company is highly positive. Though this is a commodity stock, it is a good buy for long-term investors.

PERFORMANCE INDICATORS (Rs. in crore)

Year Net Series Net Profit EPS (Rs.) Div (%) BV (%) RONW (%)
2019-20 3578.00 169.10 7.50 95.0 80.00 9.70
2020-21 3004.90 103.40 4.60 70.0 83.90 5.60
2021-22 3649.84 187.71 8.30 100.0 91.50 9.46

April 15, 2025 - First Issue

Industry Review

VOL XVI - 13
April 01-15, 2025

Formerly Fortune India Managing Editor Deven Malkan Assistant Editor A.K. Batha President Bhupendra Shah Circulation Executive Warren Sequeira Art Director Prakash S. Acharekar Graphic Designer Madhukar Thakur Investment Analysis CI Research Bureau Anvicon Research DD Research Bureau Manager (Special Projects) Bhagwan Bhosale Editorial Associates New Delhi Ranjana Arora Bureau Chief Kolkata Anirbahn Chawdhory Gujarat Pranav Brahmbhatt Bureau Cheif Mobile: 098251-49108 Bangalore Jaya Padmanabhan Bureau Chief Chennai S Gururajan Bureau Chief (Tamil Nadu) Ludhiana Ajitkumar Vijh Bhubaneshwar Braja Bandhu Behera

Want to Subscribe?


Lighter Vein

Popular Stories

E-Waste Dilemma Tackling E-Waste Via Reverse Logistics, By Vihaan Shah

A modern-day enigma and a ramification of humanity's never-ending advancements, e-waste refers to the scum con- cealed by the outward glow of ever-advancing technology.

Archives

About Us    Contact Us    Careers    Terms & Condition    Privacy Policy

Liability clause: The investment recommendations made here are based on the personal judgement of the authors concerned. We do not accept liability for any losses that might occur. All rights reserved. Reproduction in any manner, in whole or in part, in English or in any other language is prohibited.

Copyright © 1983-2025 Corporate India. All Rights Reserved.

www.corporateind.com | Cookie Policy | Disclaimer